Loading…
Champions Oncology, Inc. is projected to rise to $6.38 by 2027, a +9% move from its current price of $5.87. CSBR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.76 | $5.87 | $5.98 | +0.03% |
| May 30 | $5.72 | $5.87 | $6.03 | +0.06% |
| May 31 | $5.69 | $5.88 | $6.07 | +0.09% |
| Jun 1 | $5.66 | $5.88 | $6.10 | +0.11% |
| Jun 2 | $5.64 | $5.88 | $6.13 | +0.14% |
| Jun 3 | $5.61 | $5.88 | $6.16 | +0.17% |
| Jun 4 | $5.59 | $5.88 | $6.18 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.59 | $5.88 | $6.18 | +0.20% |
| Week 2 | $5.49 | $5.89 | $6.33 | +0.40% |
| Week 3 | $5.42 | $5.91 | $6.44 | +0.60% |
| Week 4 | $5.35 | $5.92 | $6.54 | +0.80% |
| Week 5 | $5.30 | $5.93 | $6.63 | +1.00% |
| Week 6 | $5.26 | $5.94 | $6.71 | +1.21% |
| Week 7 | $5.22 | $5.95 | $6.79 | +1.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Champions Oncology, Inc. is a technology-enabled research company that provides technology solutions for drug discovery and development in the United States.
Through its Tumorgraft technology platform, it provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies.
In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc.
and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Champions Oncology, Inc. (CSBR) operates in the Healthcare sector and currently trades at $6.01 per share. Its market capitalization is $83.46M and it holds a rank of 4341.
Forecasts indicate a long-term price path that begins near the current price and trends higher over time, with Neutral sentiment in 2026 and Bullish sentiment from 2029 onward. The 2026 average price is $6.01 with a range from $5.73 to $7.55, and the 2030 average price is $9.30. By 2040 the average is $19.61 and by 2050 it is $38.07, with the maximums reaching $30.23 in 2040 and $63.02 in 2050.
ROI figures accompany the year-by-year outlook, culminating in a 533.4 ROI by 2050.
These projections illustrate a gradual ascent in price and substantial upside in the long term, though they are estimates not guarantees and are subject to market conditions.
A major floor 6.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.2% away) — a key level to hold.
The nearest ceiling, 6.8% above — a clean break opens room to run.
A major ceiling 31.0% above — clearing it would confirm fresh momentum.
Key CSBR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CSBR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.97 | Sell | $5.96 | Sell |
| MA 10 | $6.03 | Sell | $6.00 | Sell |
| MA 20 | $6.01 | Sell | $6.01 | Sell |
| MA 50 | $5.96 | Sell | $6.03 | Sell |
| MA 100 | $6.21 | Sell | $6.17 | Sell |
| MA 200 | $6.46 | Sell | $6.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -129.38 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -2.49 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 32.27 | Neutral |
| Momentum (10) | -0.40 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 5.93 | Sell |
| ADX (14) | 5.88 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50. The SMA50 is $5.97 and the SMA200 is $6.46, outlining near-term support around $5.73 and resistance at $6.27.
The stock has a 30-day range between $5.28 and $6.84, reflecting a relatively tight trading band. Annualized volatility stands at 40%, underscoring notable, but not extreme, short-term price fluctuations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.73 | $5.87 | $7.37 | 0% | Neutral | |
| $5.21 | $6.38 | $8.18 | +9% | Neutral | |
| $5.46 | $6.81 | $8.96 | +16% | Neutral | |
| $5.87 | $7.42 | $9.97 | +26% | Bullish | |
| $6.88 | $8.82 | $12.06 | +50% | Bullish | |
| $7.57 | $9.83 | $13.65 | +68% | Bullish | |
| $8.13 | $10.67 | $15.02 | +82% | Bullish | |
| $8.43 | $11.18 | $15.94 | +90% | Bullish | |
| $8.50 | $11.39 | $16.43 | +94% | Bullish | |
| $8.85 | $11.96 | $17.45 | +104% | Bullish | |
| $13.01 | $18.34 | $28.03 | +212% | Bullish | |
| $23.39 | $35.39 | $57.95 | +503% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.73 | $5.87 | $6.85 | +0.00% |
| June 2026 | $5.01 | $5.85 | $6.96 | -0.35% |
| July 2026 | $5.13 | $6.02 | $7.23 | +2.99% |
| August 2026 | $5.14 | $6.05 | $7.32 | +0.47% |
| September 2026 | $5.04 | $5.96 | $7.25 | -1.52% |
| October 2026 | $5.08 | $6.03 | $7.38 | +1.20% |
| November 2026 | $5.14 | $6.11 | $7.51 | +1.37% |
| December 2026 | $5.00 | $5.97 | $7.37 | -2.34% |
Click any year to see its month-by-month CSBR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Champions Oncology, Inc.'s 2026 outlook centres on $5.87, within a $5.73 to $7.37 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CSBR could reach as high as $8.18, with a base case around $6.38 and support toward $5.21 — roughly +9% from $5.87. Price action looks broadly range-bound.
Expect CSBR to range from $5.46 to $8.96 through 2028. The $6.81 average target implies a +16% move from current prices. That is up +7% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CSBR price prediction for 2029 points to an average of $7.42 (low $5.87, high $9.97) — a potential gain of +26% on today's $5.87. Momentum favours further upside here.
In 2030, CSBR is projected to trade between $6.88 and $12.06, averaging $8.82 — a potential gain of +50% from today's $5.87. That is up +19% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Champions Oncology, Inc.'s 2031 outlook centres on $9.83, within a $7.57 to $13.65 range. That is up +11% on the projected 2030 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2032, CSBR could reach as high as $15.02, with a base case around $10.67 and support toward $8.13 — roughly +82% from $5.87. Buyers look set to stay in control over this stretch.
Expect CSBR to range from $8.43 to $15.94 through 2033. The $11.18 average target implies a +90% move from current prices. That is up +5% on the projected 2032 average. Momentum favours further upside here.
The CSBR price prediction for 2034 points to an average of $11.39 (low $8.50, high $16.43) — a potential gain of +94% on today's $5.87. Buyers look set to stay in control over this stretch.
In 2035, CSBR is projected to trade between $8.85 and $17.45, averaging $11.96 — a potential gain of +104% from today's $5.87. That is up +5% on the projected 2034 average. Momentum favours further upside here.
Champions Oncology, Inc.'s 2040 outlook centres on $18.34, within a $13.01 to $28.03 range. That is up +53% on the projected 2035 average. That marks a +212% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CSBR could reach as high as $57.95, with a base case around $35.39 and support toward $23.39 — roughly +503% from $5.87. Momentum favours further upside here.
Investing $1,000 in CSBR today (≈ 170.357751 CSBR) could be worth
$6,028.57
+$5,028.57 (+503%) by 2050 · US Dollar
Based on the average projected CSBR price of $35.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CSBRwould be worth at today's price.
$1,000 invested in CSBR on May 27, 2025 (≈ 166.944915 CSBR) would be worth
$979.97
-$20.03 (-2.0%) today · 0.98× · US Dollar
Based on a CSBR entry price of $5.99 vs. today's $5.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.05 | $970.25 | -3.0% |
| 1 month ago | $6.02 | $975.08 | -2.5% |
| 3 months ago | $5.99 | $979.97 | -2.0% |
| 6 months ago | $6.54 | $897.55 | -10.2% |
| 1 year ago | $5.99 | $979.97 | -2.0% |
| All time (5.0y) ago | $9.51 | $617.24 | -38.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CSBR forecast.
Our base-case forecast reaches $12.00 around 2040.
Implied market cap at $12.00: $166.64M
The multi-year forecast points to a bullish long-term trajectory for Champions Oncology. In 2026 the average price is $6.01 with a 0 ROI and NEUTRAL sentiment, followed by growth into 2027 with an average of $6.61 and a 10 ROI, and 2028 with an average of $7.09 and an 18 ROI. The outlook becomes more bullish in 2029 (avg $7.72, ROI 28.5) and strengthens through 2030 (avg $9.30, ROI 54.8) and beyond.
Looking further out, the 2040 forecast shows an average price of $19.61 with a 226.3 ROI and a max of $30.23, while 2050 projects an average of $38.07 with a max of $63.02 and a 533.4 ROI. Sentiment is listed as BULLISH from 2029 onward. These figures reflect substantial potential upside over the long horizon but remain estimates and are not guarantees, contingent on market dynamics and other factors.
Tap a question to reveal the answer.
In 2030, the forecast shows min $7.22, avg $9.30, max $12.78 with ROI 54.8 and sentiment BULLISH.
The forecast shows Neutral sentiment in 2026 (min $5.73, avg $6.01, max $7.55, ROI 0) and Neutral to Bullish through 2028, then Bullish from 2029 onward with 2030 avg $9.30 and 2050 avg $38.07 with ROI up to 533.4. These are estimates and not guarantees.
The max forecast by 2050 is $63.02, which indicates reaching $50 is within the projected upper bound of the range.
RSI14 is 50; SMA50 is $5.97; SMA200 is $6.46; support is $5.73 and resistance is $6.27. The 30-day range is $5.28 to $6.84 with 40% annualized volatility.
The 2040 forecast shows an average price of $19.61, a max of $30.23, a min of $13.78, and a ROI of 226.3, with sentiment BULLISH.
Champions Oncology, Inc. Community Discussion
0Share your Champions Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.